Direct targets of miR-302b include CDK2 and EPHA2. Transfection with miR-302b analogs inhibited the RAS/RAF/ERK/MAPK and Wnt/β-catenin signaling pathways in GC cells [28,29,30]. The gene discussed is RAF1; the disease is gastric cancer.